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COVID-19 and Multiorgan Response
Sevim Zaimy, Jun Heng Chong, BSc (Hons)y,
Vissagan Sankaranarayanany, and
Amer Harky, MBChB, MSc, MRCS*Abstract: Since the outbreak and rapid spread of
COVID-19 starting late December 2019, it has been
apparent that disease prognosis has largely been influ-
enced by multiorgan involvement. Comorbidities such as
cardiovascular diseases have been the most common risk
factors for severity and mortality. The hyperinflamma-
tory response of the body, coupled with the plausible
direct effects of severe acute respiratory syndrome on
body-wide organs via angiotensin-converting enzyme 2,
has been associated with complications of the disease.
Acute respiratory distress syndrome, heart failure, renal
failure, liver damage, shock, and multiorgan failure have
precipitated death. Acknowledging the comorbidities
and potential organ injuries throughout the course of
COVID-19 is therefore crucial in the clinical manage-
ment of patients. This paper aims to add onto the ever-
emerging landscape of medical knowledge on COVID-
19, encapsulating its multiorgan impact. (Curr Probl
Cardiol 2020;45:100618.)Introduction
A
novel coronavirus, designated the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), emerged in late December
2019 from a cluster of pneumonia cases epidemiologically
linked to a wet market in Wuhan, China.1 The disease, now known as
COVID-19, has since spread rampantly leading to a worldwide pandemic
which has precipitated draconian measures to limit its transmission.ources of support.
1
COVID-19 has demonstrated a wide spectrum of clinical manifestations,
from asymptomatic or paucisymptomatic forms, to severe viral pneumonia
with respiratory failure, multiorgan and systemic dysfunctions in terms of
sepsis and septic shock, and death.2,3 This paper aims to encapsulate the
multiorgan impact of COVID-19 reported since its outbreak.Literature Search
A comprehensive literature search was done on PubMed, SCOPUS,
Embase, Cochrane database, google scholar and Ovid to identify the
articles that discussed the novel corona virus, COVID-19 and its implica-
tions on different organs of human body. Key words used were
“COVID,” “SARS-CoV-2,” “SARS-CoV,” “2019-nCoV,” “COVID-19,”
“Novel Corona virus.” The search terms were used as key words and in
combination as MeSH terms to maximize the output from literature find-
ings. A staged literature search was done, whereby a separate literature
search was performed for each section within this article and all the rele-
vant studies were identified and summarized separately. If a paper is
reporting on many aspects of the COVID-19, then the results have been
shared between different parts of this review. The relevant articles are
cited and referenced within each section separately. No limit placed on
publication time or language of the article.
All the relevant articles were identified and screened by 3 authors; the
results are summarized in narrative manner in each relevant section
within the text of this review. A summary table of each section is pro-
vided where appropriate.BackgroundEpidemiology
A timeline of the outbreak is summarized in Table 1. As of April 11,
2020, 1,610,909 confirmed cases worldwide have been reported.4
Early investigations reported a basic reproductive number (R0) ranging
between 1.4 and 3.9, while a mean incubation period of 5.2 days5 ranging
between 1 and 14 days.6 According to the World Health Organization,4
the current estimated global mortality is 99,690 (6.19% of confirmed
cases) (Fig), the proportion of which may vary based on demographics of
a location. All ages are susceptible to infection, and viral shedding may
occur in asymptomatic individuals.7 The risk factors for poor prognosis
include advancing age and comorbidities,8 while mortality is associated2 Curr Probl Cardiol, August 2020
Table 1. Timeline of COVID-19 outbreak4
December 31, 2019 Emergence of a cluster of pneumonia of unknown etiology in Wuhan,
Hubei Province, China
January 7, 2020 Virus isolated for genome sequencing
January 11 First death reported in China
January 12 Genetic sequence available to the WHO facilitating diagnostic PCR
tests
January 30 WHO declared the outbreak as a public health emergency of
international concern (PHEIC)
February 2 1st death reported outside China (Philippines)
February 11 WHO announced name for disease—COVID-19
March 11 WHO declared COVID-19 a pandemic
April 4 Global confirmed cases exceeded 1,000000
April 11 Global confirmed case count of 1,610,909
PCR, polymerase chain reaction; WHO, World Health Organisation.with age, high Sequential Organ Failure Assessment score, and D-dimer
levels of >1 mg/mL on admission.9Virology
SARS-CoV-2 is an enveloped, positive-sense RNA virus, and belongs to
the b-coronavirus genus (sarbecovirus subgenus, orthonavirinae subfam-
ily).1 It represents the seventh member of the Coronaviridae family known
to infect humans. Its counterparts include 4 strains of low pathogenicity
(229E, OC43, NL63 and HKU1), as well as 2 other b-coronaviruses which
caused the previous outbreaks of severe and potentially fatal respiratoryFIG . Weekly cumulative data on global confirmed cases and deaths of COVID-19.4
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tract infections—SARS-CoV and Middle East respiratory syndrome-Coro-
naVirus (MERS-CoV).10
SARS-CoV-2 more closely resembles SARS-CoV (79% sequence
identity) than MERS-CoV (50% sequence identity).11 It also shares the
same cellular receptor as SARS-CoV which is the angiotensin-converting
enzyme 2 (ACE2) receptor.12 ACE2 receptors are enriched in alveolar
epithelial type II cells of lung tissues,13 as well as extrapulmonary tissues
such as the heart, endothelium, kidneys, and intestines,14,15 which might
play a role in the multi-organ effects of COVID-19.Origin and Route of Transmission
Current evidence indicates an initial animal-to-human transmission
from wild animals traded at the Huanan seafood market in Wuhan. The
origin and mechanism of which remain to be clarified—while some geno-
mic studies suggested bats as the natural reservoir,16 others suggested
pangolins.17 As the outbreak progressed, person-to-person transmission
remains the main mode of spread. This is through (1) respiratory droplets
released via coughing or sneezing, (2) aerosol, typically during aerosol-
generating clinical procedures, and (3) mucosal membrane contact with
fomites.18,19 Faecal-oral transmission has been speculated,20 given the
detection of viral RNA in stools, reported gastrointestinal (GI) symptoms,
and ACE2 expression along the GI-tract.21 No evidence of intrauterine or
transplacental transmission has been reported.22-24Respiratory Involvement of COVID-19Initial Presentation
In a study that analyzed 138 COVID-19 patients,25 the most common
clinical features were fever (99%), fatigue (70%), dry cough (59%),
anorexia (40%), myalgias (40%), dyspnea (31%), and sputum produc-
tion (27%). Other cohort studies have reported a similar range of clini-
cal findings.3,26-28 However, fever might not be a universal finding,
with 1 study reporting only 20% of their patients with very low grade
fever (<100.4˚F/38˚C) and another2 reporting fever in 44% of patients.
Headache, sore throat and rhinorrhea have also been noted as less com-
mon symptoms.29 Although not highlighted in the aforementioned stud-
ies, anosmia and dysgeusia (smell and taste disorders) have been
reported as well (Table 2).294 Curr Probl Cardiol, August 2020
Table 2. Clinical syndromes associated with COVID-19 in adults73
Mild illness Resembles upper respiratory tract infection. May have
nonspecific symptoms such as fever, fatigue, cough, (with or
without sputum production), anorexia, malaise, muscle pain,
sore throat, dyspnea, nasal congestion, or headache.
Rarely, patients may also present with diarrhea, nausea, and
vomiting.
Pneumonia Pneumonia present but no signs of severe pneumonia and no
requirements for supplemental oxygen.
Severe pneumonia Fever or suspected respiratory infection, plus one of the
following: respiratory rate > 30 breaths/min; severe
respiratory distress or SpO2  93% on room air.
Acute Respiratory Distress
Syndrome (ARDS)
Within 1 week of known clinical insult or worsening respiratory
symptoms. Chest radiographs show bilateral opacities which
cannot be fully explained by volume overload, lobar or lung
collapse, or nodules. Cardiac failure and fluid overload must
be ruled out, need objective assessment (eg,
echocardiography) to exclude hydrostatic causes if no risk
factors are present.
 Mild ARDS: 200 mm Hg < PaO2/FiO2 a  300 mm Hg
(with PEEP or CPAP  5 cmH2O, or nonventilated)
 Moderate ARDS: 100 mm Hg < PaO2/FiO2  200 mm Hg
(with PEEP  5 cmH2O, or nonventilated)
 Severe ARDS: PaO2/FiO2  100 mm Hg (with PEEP  5
cmH2O, or nonventilated)
 When PaO2 is not available, SpO2/FiO2  315 suggests
ARDS (including in nonventilated patients)
Sepsis Life-threatening organ dysfunction caused by dysregulated
host response to suspected or proven infection. Signs of
organ dysfunction include: difficult or fast breathing, low
oxygen saturation, altered mental status, reduced urine
output, fast heart rate, weak pulse, cold extremities or low
blood pressure, skin mottling, or laboratory evidence of
thrombocytopenia, high lactate, coagulopathy, acidosis or
hyperbilirubinemia.
Septic shock Persisting hypotension despite fluid resuscitation, requiring
vasopressors to maintain mean arterial pressure (MAP).
MAP  65 mm Hg and serum lactate level > 2 mmol/L.
ARDS, Acute Respiratory Distress Syndrome; CPAP, continuous positive airway pressure ther-
apy; MAP, Mean Arterial Pressure; PEEP, positive end-expiratory pressure.Disease Progression
The most frequent, serious manifestation of COVID-19 infection
seems to be pneumonia, which is characterized by cough, fever, dyspnea
and bilateral infiltrates displayed on radiographic chest imaging. Unfortu-
nately, there are no specific clinical features that discern COVID-19 from
other viral respiratory illnesses.29 Although most patients will only expe-
rience mild symptoms of the disease, some patients will experience rapidCurr Probl Cardiol, August 2020 5
Table 3. Summarized interpretations of median time data obtained fromWang et al and Huang
et al3,25
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ARDS, Acute Respiratory Distress Syndrome; ICU, intensive care unit.progression of their symptoms over the span of a week (Table 3).3,25 One
study30 found that 17% of their patients developed Acute Respiratory
Distress Syndrome (ARDS) and among these, 65% rapidly worsened and
died from multiple organ failure. In a study focusing on the associated
risk factors,31 it was reported that ARDS was greatly associated with
older age (>65 years old), diabetes mellitus, and hypertension. For most
cases, bilateral lower zone consolidation (identified through chest x-ray)
peaked at 10-12 days from symptom onset.32Radiological Manifestations
COVID-19 infection shares similar radiological features33 to those of
other viral pneumonia.34 The hallmarks of COVID-19 on computed
topography imaging are bilateral and peripheral ground-glass opacities,
and consolidative pulmonary opacities. Crazy paving patterns have also
been observed.27 A staging system for using computed topography
images has been reported33 and is summarized in Table 4.
Interestingly, the development of pleural effusions and progression to a
mixed pattern of ground-glass opacities and consolidative opacities have
been reported in late-stages.35Cardiovascular Involvement of COVID-19COVID-19 and Pre-Existing Cardiovascular Disease
Patients with existing cardiovascular disease (CVD) are at a greater
risk of suffering from severe COVID-19 and having poorer prognosis. A6 Curr Probl Cardiol, August 2020
Table 4. Stages of COVID-19 infection based on CT images33
Ultra-early Refers to the stage without clinical manifestations, patients are often
asymptomatic, but normally is seen 1-2 weeks after COVID-19
exposure. Main imaging manifestations are single or multifocal GGO,
patchy consolidative opacities, pulmonary nodules encircled by GGO
and air bronchograms.
Early Refers to an early symptomatic presentation, 1-3 days after clinical
manifestations. This is the most observed stage through radiological
imaging (54%). Main imaging manifestations are single or double GGO
combined with interlobular septal thickening. Pathological processes
during this stage are dilatation and congestion of the alveolar septal
capillary, interlobular interstitial edema and exudation of fluid in
alveolar cavity.
Rapid progression Refers to 3-7 days after clinical manifestations, where the pathological
features of this stage are accumulation of exudates in the alveolar
cavity, vascular expansion and exudation in the interstitium. These
pathological features lead to the further aggravation of alveolar and
interstitial edema. Fibrous exudation forms bonds between each
alveolus through the interstitial space to form a fusion state. Main
radiological manifestations are large, light consolidative opacities with
air bronchograms.
Consolidation Refers to the second week after initial symptomatic presentation. Main
pathological features are fibrous exudation of the alveolar cavity and
the reduction of capillary congestion. CT imaging can show multiple
consolidations reducing in size and density, compared to before.
Dissipation Refers to 2-3 weeks after onset of symptoms. CT imaging can show
dispersed, patchy consolidative opacities, reticular opacities, bronchial
wall thickening and interlobular septal thickening.
GGO, ground glass opacities.meta-analysis comprising of 46,248 patients with confirmed COVID-19
found that the most common co-morbidities were hypertension (17%),
diabetes (8%), and CVD (5%).36 CVD and hypertension have also been
more prevalent in the severe patient group as compared to non-severe
cases (odds ratio of 3.42 and 2.36, respectively).36 Existing CVD is also
associated with higher mortality which is summarized in Table 5.16Table 5. Association between CVD and risk of mortality from COVID-19 as reported by Zhou
et al16
Survivors Nonsurvivors
Coronary heart disease 8% 24%
Hypertension (CVD risk factor) 30% 48%
DM (CVD risk factor) 13.9% 31.4%
Smoking (CVD risk factor) 4.4% 9.3%
CVD, cardiovascular disease; DM, diabetes mellitus.
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On the other hand, it is widely agreed that COVID-19 can also have
adverse effects on cardiovascular health itself, causing or aggravating
damage to the heart. There are reports of cardiogenic involvement in
patients without known CVD37 as well as cases with solely cardiac
presentations.38,39Mechanism of Cardiovascular Involvement
The exact mechanism of cardiovascular involvement in COVID-19 is
not yet well understood, however elevated cardiac biomarker levels are
commonly seen. In a study by Wang et al, 7.2% of patients had either ele-
vated troponin levels or new electrocardiography or echocardiography
abnormalities suggestive of cardiac injury.25
ACE2 is highly expressed in the heart, providing opportunity for
ACE2-dependent myocardial infection. Cytokine storm from systemic
inflammation and the hypoxic state from ARDS inducing excessive
extracellular calcium levels leading to myocyte apoptosis are also
possible mechanisms of damage.40 Surge in cytokine levels due to
hyperinflammatory response or secondary hemophagocytic lymphohis-
tiocytosis and increased myocardial demand in the setting of acute
infection can lead to atherosclerotic plaque instability and myocardial
injury, increasing the risk of acute myocardial infarction.41 Blood
pressure abnormalities can also be seen in response to the illness.41
Additionally, palpitations due to arrhythmia have been observed.41,42
The type of arrhythmias are variable and etiology can be multi-facto-
rial, ranging from hypoxic state due to ARDS to myocarditis.41 Hu et
al and Zeng et al also reported patients with reduced ejection fraction
and heart enlargement.39,43 Therefore, possible long-term effects of
COVID-19 on cardiovascular system such as risk of heart failure
should be considered and further investigated.Renin-Angiotensin-Aldosterone System Inhibitors and
COVID-19
Effects of angiotensin converting enzyme inhibitors and angioten-
sin II receptor blockers on COVID-19 susceptibility and prognosis
have been controversial. Some evidence suggests that increasing
ACE2 expressions facilitate COVID-19 infection,44 while others8 Curr Probl Cardiol, August 2020
Table 6. Data on AKI in patients with COVID-19 from major clinical cohort studies
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28 (15%) 5% DM: 19%
HTN: 30%
AKI, acute kidney injury; CKD, chronic kidney disease; CVD, cardiovascular disease; DM,
diabetes mellitus; ESKD, end stage kidney disease; HTN, hypertension.
General comments: The incidence of AKI ranges from 0.5% to 19%, however the study that
reported the upper value75 only reported data from critically ill patients, thus explaining the
very high incidence rate. Most of the patients included in these studies presented with
normal kidney function, with no underlying CKD. In terms of median time for developing AKI
from hospital admission, Zhou et al. reports a median of 15 days, whereas Cheng et al.
reports most patients developing AKI within 7 days of admission.16,74
*Used KDIGO criteria for AKI definitions.suggest potential beneficial effects of reducing lung injury.45 There-
fore, changes to their standard indications on the basis of COVID-19
is not currently recommended.40Curr Probl Cardiol, August 2020 9
Renal Involvement of COVID-19Renal Manifestations
Acute kidney injury (AKI) is the abrupt loss of kidney function that
develops within 7 days. Its incidence has been observed with SARS and
MERS-CoV.46 The reported data of AKI in COVID-19 patients are com-
piled in Table 6.
Although the exact pathogenesis of kidney involvement in COVID-19
infection is unclear, it is reported that AKI in COVID-19 accompanies
sepsis, multiorgan failure and shock, suggesting the cause of AKI to be
acute tubular necrosis.29 Alternatively, a study based on single-cell tran-
scriptome analysis47 proved ACE2 receptor expression in kidney cells,
suggesting the plausibility of direct renal cellular damage from SARS-
CoV-2. This is further supported by the recent detection of SARS-CoV-2
in a urine sample from an infected patient.46 Findings of one of the first
systematic investigations of kidney function in COVID-19 patients48 are
summarized in Table 7.Role of Kidney Replacement Theory
In some patients, the metabolic consequences of AKI cannot be ade-
quately controlled with conservative management; hence renal replace-
ment therapy (RRT) can be required. There is little to no evidence that
the starting time,49 modality50 and dose51 of RRT has any difference in
outcomes. However, convection therapies are known to cause filter clots
and use consumables (eg, tubing and dialysate and/or replacement solu-
tion bags), which can increase costs and exacerbate the issues faced by an
overwhelmed hospital. Continuous RRT (CRRT) has been successfully
applied in the treatment of SARS,52 MERS,53 and sepsis.46 A hemofiltra-
tion dose of 6 L/min removed proinflammatory cytokines and improved
Sequential Organ Failure Assessment score at day 7 in septic patients,54
suggesting the effectiveness of CRRT in the management of renal mani-
festations in COVID-19.
Gastrointestinal Involvement of COVID-19Gastrointestinal Symptoms
A significant number of patients reported GI symptoms such as diar-
rhea, nausea, vomiting, and abdominal pain, with some reporting these
symptoms as their sole presenting complaint.32 The incidence of GI10 Curr Probl Cardiol, August 2020
Table 7. Summarized findings and interpretations of a systematic review of COVID-19 patients with renal dysfunction48
Results General comments
Number of patients included (n = 193) 128 nonsevere
65 severe
55 (28%) developed AKI (used KDIGO criteria).




Suggests that renal dysfunction occurred before or at
admission, indicating that viral replication of SARS-CoV-2
might play a role in the destruction of renal cells.
Exhibition of proteinuria and hematuria Proteinuria: 88 (60%)
Hematuria: 71 (48%)
Significant number of patients presented with these
exhibitions, offering a potential time window for starting
interventions to protect kidney function.
Exhibition of elevated level of BUN 59 (31%) Median time from onset of admission to presence of BUN
increase was 2 days.
Exhibition of elevated level of SCr 43 (22%) Median time from onset of admission to presence of SCr
increase was 5 days.
Exhibition of radiographic abnormalities of
kidneys (N = 110)
106 (96%) CT images of the 2 groups (severe and non-severe) are clearly
distinguishable, suggesting a presence of renal dysfunction
in COVID-19.
Difference in mortality risk of COVID-19
patients with and without AKI
Estimated hazard ratio indicates that the mortality risk of COVID-19 patients with AKI is »5.3x
(P< 0.001) higher than the mortality risk of COVID-19 patients without AKI.
AKI, acute kidney injury; BUN, blood urea nitrogen; KDIGO, Kidney Disease Improving Global Outcomes; SCr, serum
creatinine.
Conclusions: BUN and SCr are key predictors of AKI and they were found to be significantly higher in non-severe cases of COVID-19 compared to other
commonly known pneumonia. Both high levels of BUN and SCr were commonly observed in severe and deceased cases across the course of COVID-19.
Unlike BUN, for other pneumonia cases, there were no reported elevated SCr levels. Occurrence of kidney dysfunction in COVID-19 patients could be due
to kidney-lung crosstalk76 for the following reasons: renal cells have the potential to be target sites for SARS-CoV-2 and inflammatory responses following
lung impairments could damage the kidney, where this kidney-lung crosstalk could lead to a “cytokine storm” that acutely induces multi-organ failure and
death. Furthermore, direct renal cellular damage is consistent with another report77 which found acute renal tubular damage in 6 COVID-19 cases from























symptoms, alongside the detection of SARS-CoV-2 RNA in stool sam-
ples of infected patients,55 suggest that ACE2 receptors highly expressed
in the GI tract are another target for SARS-CoV-2 infection.Liver Injury in COVID-19 Patients
Mild and transient liver injury, as well as severe liver damage can
occur in COVID-19. Wong et al indicated that 14.8-53.1% of COVID-19
patients had abnormal levels of alanine aminotransferase, aspartate ami-
notransferase, and bilirubin during the course of the disease, with biliru-
bin showing the smallest elevation. Furthermore, they reported that
severity of liver damage is proportional to that of COVID-19.32 Gamma-
glutamyl transferase was elevated in 54% of patients in 1 cohort study
that included 56 COVID-19 patients.56Immune System Response
The immune response is undeniably one of the key determiners of the
susceptibility and severity of the disease. While weakened immune sys-
tem can increase the risk of severe COVID-19, hyperinflammatory
response to the infection can be responsible for the commonly seen com-
plications by causing organ damage.
The surge in inflammatory parameters like IL-2, IL-7, granulocyte-col-
ony stimulating factor, interferon-g inducible protein 10, monocyte che-
moattractant protein 1, macrophage inflammatory protein 1-a, and tumor
necrosis factor-a can be caused by an imbalanced immune response lead-
ing to cytokine storm or secondary hemophagocytic lymphohistiocyto-
sis.57 Along with typical cardinal features like hyperferritinaemia,
cytopenia, and unremitting fever; pulmonary and cardiac involvement
including ARDS and acute coronary syndrome can also result from
hypercytokinaemia.57,58
Moreover, accumulating evidence suggests that this hyperinflamma-
tory state can be predictors of morbidity and mortality in a significant
subgroup of patients.57 In a multicenter retrospective study, it was found
that ferritin and IL-6 levels were more elevated in the non-survivor group
as compared to the survivors.59 This is also supported by findings of Qin
et al who recently discovered that severe cases had higher neutrophil-
lymphocyte ratio, lower percentages of basophils, eosinophils, and mono-
cytes, as well as elevated inflammatory biomarkers and cytokines. Addi-
tionally, the number of suppressor and helper T cells, B cells, and NK12 Curr Probl Cardiol, August 2020
cells were decreased in the severe group.60 Septic shock is also reported
in 4%-8% of patients in several case series.61
Therefore, it is paramount for all patients with severe COVID-19
to be screened for hyperinflammation using ferritin levels, platelet
count, and erythrocyte sedimentation rate along with the HScore.57,62
Once identified, therapeutic approach is to suppress the immune sys-
tem. However, it is a difficult decision to determine whether anti-
inflammatory effects of treatment outweigh the risk of impairing the
immune system that is trying to fight the infection. In addition to the
options of steroids and intravenous immunoglobulins, IL-6 receptor
antagonist monoclonal antibodies like tocilizumab and sarilumab,
anakinra, Janus kinase inhibitor and CC chemokine receptor 5 antago-
nists are also in the clinical trial stage for treatment of cytokine
release syndrome in COVID-19.61
Other Organ InvolvementThe Nervous System
It has been suggested that viral invasion of the central nervous system
by SARS-CoV2 is possible by the synapse-connected route observed
with other coronaviruses such as SARS-CoV and can lead to several neu-
rological complications including ataxia, seizures, neuralgia, uncon-
sciousness, acute cerebrovascular disease and encephalopathy.61,63 Mao
et al reported that 36.4% of their cohort had neurologic manifestations,
the severe group being more likely to have acute cerebrovascular disease,
impaired consciousness and skeletal muscle injury.64 Furthermore, Li et
al proposed that this potential viral invasion might play a partial role in
the pathophysiology of acute respiratory failure in COVID-19 patients.63The Coagulation Cascade
Disseminated intravascular coagulation is another common complica-
tion of COVID-19 reported in 71.4% of nonsurvivors compared to only
0.6% of survivors.65 It has also been found that use of anticoagulation
with low molecular weight heparin (LMWH) or unfractionated heparin
improved outcomes in severe cases with coagulopathy.66Rhabdomyolysis as a Potential Complication of COVID-19
One case of rhabdomyolysis as a potential late complication of
COVID-19 has been reported in China. The possibility of under-diagnosisCurr Probl Cardiol, August 2020 13
due to muscle pains being a common symptom of COVID-19 as well as
creatine kinase and myoglobin levels not being routinely tested is also
highlighted in the letter.67Clinical Management
Current interventions are supportive, as effective antiviral treatment
has not yet been identified. The clinical management of adult patients are
guided by international guidelines as well as local experience and
regional outcomes.68,69
Patients with signs of pneumonia and those of the high-risk group are
indicated for hospitalization. Those with mild flu-like symptoms are dis-
charged, supplemented with symptomatic treatment and advised to return
in case of illness worsening.Oxygen and/or Respiratory Support
Noninvasive oxygenation is generally not recommended in hypoxemic
COVID-19 patients, particularly the use of high nasal flow oxygen. Non-
invasive ventilation with continuous positive airway pressure, rather than
bilevel positive airway pressure, is preferred. A target peripheral oxygen
saturation (SpO2) of 92%-96% has been suggested.70 Endotracheal intu-
bation is indicated upon acute deterioration or failure of response towards
standard oxygen therapy. Higher, instead of lower, positive end-expira-
tory pressure is recommended. For severe ARDS, prone ventilation for
16 hours/day is suggested.71 Additional rescue interventions include
extra-corporeal membrane oxygenation.Management of Nonrespiratory Organ Failure
Upon recognition of sepsis, standard care72 is to be commenced as
soon as possible. This includes initiation of fluid bolus and vasopressors
for hypotension. Prophylaxis against venous thromboembolism is
strongly recommended, LMWH preferred over unfractionated heparin, as
well as nonpharmacological modalities such as intermittent pneumatic
compression stockings. As mentioned above, AKI can be managed by
CRRT. Intermittent RRT has been suggested to be as effective.72 Cardiac
support can be managed with direct input from the cardiology team and
inotropic support if required.14 Curr Probl Cardiol, August 2020
Pharmacotherapy
Routine corticosteroids are not recommended, unless for trial purposes
or for other indications such as adrenal insufficiency, asthma, or Chronic
Obstrcutive Pulmonary Disease.
Conclusion
Multiorgan involvement has been apparent since the emergence of
COVID-19—the rapidity of disease progression is widely influenced by
the presence of comorbidities and of extrapulmonary organ injuries.
ARDS, heart failure, renal failure, shock, and multiorgan failure precip-
itate death. Full attention to the comorbidities and potential organ inju-
ries is therefore crucial in the implementation of preventative and
protective measures. Acknowledging this could help in triaging the
management of individual patients, minimizing the risk of decompensa-
tion. Alongside the rapid pace at which scientific results are shared, this
paper hopes to add onto the ever-emerging landscape of medical knowl-
edge on COVID-19.
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